FDA Grants Priority Review to Sanofi's Venglustat for Type 3 Gaucher Disease
SNY is trading near its 52-week low of $42.325 (5.7% above the low).
Summary
Sanofi's venglustat has been granted FDA Priority Review for its New Drug Application (NDA) to treat type 3 Gaucher disease, with a target action date of November 25, 2026. This follows the Breakthrough Therapy designation the drug received in March for the same indication. If approved, venglustat would be the first treatment in the US to address the progressive neurological manifestations of this rare lysosomal storage disorder, representing a significant pipeline advancement and potential market opportunity for Sanofi.
At the time of this announcement, SNY was trading at $44.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $107B. The 52-week trading range was $42.33 to $53.03. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.